Prostavac

Teleconference – A New PROSPECT for Prostate Cancer Patients this Tuesday at 6 p.m.

Malecare will be holding a free teleconference this Tuesday, April 30 at 6.m. I will be speaking with Dr. James Gulley who is the Deputy Chief of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute and the Director of the Clinical Trials Group. He also serves as a Senior Investigator within [...]

By |2013-04-26T15:03:25-04:00April 26th, 2013|Advanced Prostate Cancer, Drugs & Treatments, Firmagon (degarelix), ipilimumab, MDV3100, NIH, Prostate Ponderings, Provenge, Research, Uncategorized, Understanding APC, vaccines, Xtandi, Yervoy, Zytiga|9 Comments
Read More

Bavarian Nordic Initiates Pivotal Phase 3 Trial of PROSTVAC® Prostate Cancer Immunotherapy

Bavarian Nordic A/S (BAVA) announced on November 15, that its subsidiary, BN ImmunoTherapeutics has started the pivotal Phase 3 trial of PROSTVAC® for men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The trial is being conducted under a Special Protocol Assessment agreement with the FDA. Notice this trial has the same criteria as [...]

By |2021-02-17T10:28:06-05:00January 17th, 2012|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, FDA, On The Horizon, Prostvac, Uncategorized, vaccines|0 Comments
Read More
Go to Top